She added that all tested vaccine samples produced antibodies that succeeded in neutralizing the original and mutated Delta virus, while 87 percent of the samples succeeded in neutralizing the mutant “Omicron”.
“We are very pleased with these results,” the company’s chief medical officer, Juan Carlos Jaramio, said in a statement, noting that it supported the results of a previous experiment that showed a better immune response after receiving two doses of the vaccine.
Valneva expects to receive regulatory approvals for its vaccine within two months or a little more.
If the vaccine is approved in Europe, the delivery of doses there is expected to begin in April.
.
